Publications by authors named "Kim Gaspar"

Claim this Profile
S
Safety of unconventional antibody-drug conjugate L-DOS47 in a phase I/II monotherapy study targeting advanced NSCLC.
Rodryg Ramlau, Dariusz M Kowalski, Aleksandra Szczęsna, Cezary Szczylik, Young Ou, Kim J Gaspar

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy.
Bruna Victorasso Jardim-Perassi, Pietro Irrera, Oluwaseyi E Oluwatola, Dominique Abrahams, Veronica C Estrella, Kim J Gaspar

Biomedicines· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
L-DOS47 enhances response to immunotherapy in pancreatic cancer tumor.
Bruna Victorasso Jardim-Perassi, Pietro Irrera, Dominique Abrahams, Veronica C Estrella, Bryce Ordway, Kim J Gaspar

bioRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC.
Sarina Piha-Paul, George Simon, Chandra P Belani, Heman Chao, Kim Gaspar

JTO Clin Res Rep· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Production and characterization of a camelid single domain antibody-urease enzyme conjugate for the treatment of cancer.
Baomin Tian, Wah Yau Wong, Elda Hegmann, Kim Gaspar, Praveen Kumar

Bioconjug Chem· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis